Related Experiment Video
Updated: Sep 12, 2025

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Oral Anticoagulant Management for Peripheral Vascular Disease
Bianca Mulaney-Topkar1, Anahita Dua1
1Division of Vascular and Endovascular Surgery, Massachusetts General Hospital, Wang 440, 55 Fruit Street, Boston, MA, USA.
None:
The following article summarizes the main oral antiplatelet and anticoagulant medications that are currently FDA-approved and available in the market. We then summarize recommendations for their use by peripheral artery disease (PAD) severity (asymptomatic PAD, symptomatic PAD, and CLTI), as well as by procedural intervention (whether patients have undergone endovascular or open revascularization) based on existing trial data. Finally, we take a look at some of the latest research regarding optimal antithrombotic therapy as a harbinger of future guideline updates.
More Related Videos
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Peripheral Artery Disease V: Postoperative Nursing Management
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis IV: Nursing Management
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Peripheral Artery Disease III: Interprofessional Care

